Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Anbc, Inc. (SYUP)
Shanghai, CN
Shanghai Yutong Pharma, Inc., a company based in Shanghai, China, specializes in the development, manufacturing, and distribution of both traditional Chinese herbal remedies and cutting-edge biological pharmaceuticals within the People's Republic of China. Their diverse product portfolio addresses a wide range of health concerns. Noteworthy offerings include Qilisheng, crafted to strengthen the immune system and promote overall vitality. Oral solutions such as Qi-ju-di-huang are formulated to support kidney and liver function, while Qing-re-jie-du serves to reduce fever and alleviate heat. Sheng-mai-yin is designed to conserve vital energy and replenish bodily fluids, and Xiao-qing-long provides relief from coughs and difficulty breathing. The company also produces various syrups: Shen-bao targets the treatment of impotence and spermatorrhoea; Ban-xia offers cough suppression; and Gan-mao-zhi-ke combats symptoms of the flu, coughs, and nasal congestion. Further herbal preparations encompass Ban-lan-gen for common cold and influenza relief; Gan-mao-qing-re, which helps to mitigate minor body aches, pains, and fever; Huang-dan-yin-chen, utilized in managing jaundice and infectious hepatitis; and Liu-shen-qu, prescribed for instances of vomiting and dysentery. These pharmaceutical goods are supplied to distributors via a wholesale model.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -33.33% | +0.00% | +0.00% | +100.00% | -96.67% | -99.46% | -99.67% | -99.75% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+10.0% ★
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-70.9%
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+23.7%
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+42.4% ★
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+72.8% ★
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+268.5%
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00×
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lee Lishia | Secretary and Treasurer | — | female |
| Lu Jiang'an | President, Principal Financial Officer and Principal Accounting Officer | — | male |
| Wei Dong | Chief Executive Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SYUP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
